{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:29:17Z","timestamp":1777426157574,"version":"3.51.4"},"reference-count":0,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6,1]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:bold>\n Drug-induced liver enzyme abnormalities may indicate hepatic injury. Antipsychotic drugs also may cause increase in the liver enzymes and serum bilirubin levels. The present report evaluates the case of a patient with risperidone-associated hepatocellular damage.\n <\/jats:p>\n \n Case summary:<\/jats:bold>\n A 19-year-old Caucasian man was admitted to the Department of Psychiatry with paranoid schizophrenia and risperidone was administered in a gradually increasing dose up to 8 mg\/day. After 3 weeks of treatment, he experienced asthenia and weight loss. The level of aspartate aminotransferase was 283 IU\/L (normal: <30 IU\/L), and the alanine aminotransferase level was 778 IU\/L (normal: <36 IU\/L). Treatment with risperidone was immediately discontinued. Six days after drug withdrawal, the alanine aminotransferase level fell more than 50%, and a complete return to normalcy was seen within 2 months.\n <\/jats:p>\n \n Results:<\/jats:bold>\n In the present case, a possible causal association between risperidone and hepatocellular damage has been observed due to the temporal relationship between the administration of the drug and the onset of hepatic abnormalities, and a following rapid recovery after stopping the drug. As the hepatic damage could be related to the plasma concentration of risperidone which is highly influenced by the hepatic enzyme CYP2D6, the patient was genotyped for\n CYP2D6<\/jats:italic>\n . He was classified as homozygous wild type for\n CYP2D6<\/jats:italic>\n .\n <\/jats:p>\n \n Conclusions:<\/jats:bold>\n The risk for developing hepatotoxicity during risperidone therapy cannot be supported by the patient\n CYP2D6<\/jats:italic>\n genotype. In clinical practice, it may be recommended to obtain baseline liver function tests before starting risperidone and regular screening for liver enzyme changes during therapy.\n <\/jats:p>","DOI":"10.1515\/dmdi-2013-0064","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T16:02:27Z","timestamp":1394035347000},"page":"123-126","source":"Crossref","is-referenced-by-count":12,"title":["Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity"],"prefix":"10.1515","volume":"29","author":[{"given":"Enrique","family":"L\u00f3pez-Torres","sequence":"first","affiliation":[{"name":"Neuropediatric Unit, Xanit International Hospital, Malaga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"S\u00fcveges","sequence":"additional","affiliation":[{"name":"Medical and Health Science Center, Department of Psychiatry, University of Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva M.","family":"Pe\u00f1as-LLed\u00f3","sequence":"additional","affiliation":[{"name":"CICAB Clinical Research Centre, Extremadura University Hospital and Medical School, Servicio Extreme\u00f1o de Salud, Badajoz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Do\u00f1a","sequence":"additional","affiliation":[{"name":"CICAB Clinical Research Centre, Extremadura University Hospital, Badajoz and University of Extremadura, CU Plasencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Dorado","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University Hospital Virgen de la Victoria, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"LLerena","sequence":"additional","affiliation":[{"name":"CICAB Clinical Research Centre, Extremadura University Hospital, Badajoz; and CIBERSAM, ISCIII, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Berecz","sequence":"additional","affiliation":[{"name":"Medical and Health Science Center, Department of Psychiatry, University of Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2014,3,6]]},"container-title":["Drug Metabolism and Drug Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmdi-2013-0064\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmdi-2013-0064\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:35:45Z","timestamp":1765524945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmdi-2013-0064\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,6]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,11]]},"published-print":{"date-parts":[[2014,6,1]]}},"alternative-id":["10.1515\/dmdi-2013-0064"],"URL":"https:\/\/doi.org\/10.1515\/dmdi-2013-0064","relation":{},"ISSN":["2191-0162","0792-5077"],"issn-type":[{"value":"2191-0162","type":"electronic"},{"value":"0792-5077","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3,6]]}}}